<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CEL-SCI Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/cel-sci-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MNKD) Why Phase II is the Sweet Spot for Biotech Investing</title>
		<link>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385#comments</comments>
		<pubDate>Wed, 13 Apr 2011 16:23:10 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEL-SCI Corporation]]></category>
		<category><![CDATA[CVM]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Electro-optical Sciences Inc]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[MELA]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71385</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Healthcare Expert Wednesday, April 13, 2011: Issue #1490 I recently received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phase II trials. Would Rory McIlroy have liked a do-over on Sunday at Augusta? Phase II trials are my favorite time to get involved in a biotech company. I’ll explain why in a moment. But first, a quick review of the phases of clinical trials… The Three Distinct Phases of Clinical Trials Before a new, experimental drug is tried in humans, it’s put to work in test tubes and then animals. Once it’s ready for human trials, it’s tested in three distinct phases. The Phase I trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GOL) GOL Linhas Aereas Inteligentes S.A. Prices Global Share Offering</title>
		<link>http://www.stockbloghub.com/2009/10/13/gol-gol-linhas-aereas-inteligentes-s-a-prices-global-share-offering/17467</link>
		<comments>http://www.stockbloghub.com/2009/10/13/gol-gol-linhas-aereas-inteligentes-s-a-prices-global-share-offering/17467#comments</comments>
		<pubDate>Tue, 13 Oct 2009 20:16:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Regional Airlines]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CEL-SCI Corporation]]></category>
		<category><![CDATA[CVM]]></category>
		<category><![CDATA[GOL]]></category>
		<category><![CDATA[GOL Linhas Aéreas Inteligentes S.A.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17467</guid>
		<description><![CDATA[On Friday, GOL Linhas Aereas Inteligentes S.A. (GOL) announced that its global offering of 38,005,000 preferred shares Incorporatedluding preferred shares in the form of American Depositary Shares (&#8220;ADSs&#8221;), by the company and ASAS Investment Fund, the company&#8217;s controlling shareholder was priced on October 8, 2009. The offering of preferred shares in Brazil has been registered with the Comissao de Valores Mobiliarios (CVM), the Brazilian securities commission. ASAS Investment Fund will invest the entire the proceeds (excluding proceeds from the sale of any preferred shares upon the exercise of the over-allotment option) received from the sale of preferred shares in common shares newly issued by the company. ASAS Investment Fund has granted the international and Brazilian underwriters an option to purchase up to 5,182,500 additional preferred shares Incorporatedluding preferred shares in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/gol-gol-linhas-aereas-inteligentes-s-a-prices-global-share-offering/17467/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

